In conclusion, anti-VEGF drugs combined with vitrectomy showed significant improvements in BCVA at three months as compared to vitrectomy alone, indicating their potential effectiveness for diabetic vitreous hemorrhages. This evidence concerns the gene VEGFA and hemorrhage.